Q1 Earnings Forecast for TARS Issued By Lifesci Capital

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.48) EPS and Q3 2025 earnings at ($0.31) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group boosted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Guggenheim reissued a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday. Barclays decreased their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $43.55 on Friday. The stock’s 50 day moving average price is $51.14 and its 200 day moving average price is $43.00. The firm has a market cap of $1.66 billion, a P/E ratio of -11.43 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TARS. Creative Planning purchased a new stake in Tarsus Pharmaceuticals in the third quarter valued at approximately $362,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after buying an additional 2,879 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $3,608,000. Harbor Capital Advisors Inc. raised its position in shares of Tarsus Pharmaceuticals by 57.5% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock worth $595,000 after buying an additional 6,612 shares during the period. Finally, Emerald Advisers LLC purchased a new stake in Tarsus Pharmaceuticals during the third quarter valued at about $4,812,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.